Buy, Sell or Hold: Merck & Company (MRK-N) — Stock Predictions at Stockchase

skip to content

Home Daily Stock Opinions and Ratings Merck & Company (MRK-N)

NYSE:MRK

106.39

0.47 (0.44%) 1d

STRONG BUY

He's been recommending this for 15 minutes. Has the most confidence in this name. They reported positive results on their cholesterol pill this morning. Strong technicals, too.

biotechnology / pharmaceutical

HOLD

Reasonable multiple. Has one of the great oncology drugs of all time, Keytruda.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Jul 15/22, Up 19%) Defensive. Great pipeline. Best in class in pharma/healthcare.

biotechnology / pharmaceutical

HOLD

Sell PFE to buy MRK? Likes and owns them both. MRK is more in the immuno oncology and cancer space, whereas PFE is more diversified. Defensive and growth characteristics. MRK hit a new high today. PFE hasn't done as well, but has performed over the last 2 years. Own both for different reasons. May want to trim in early part of next cycle. Yield is 2.6%.

biotechnology / pharmaceutical

BUY

Allan Tong’s Discover Picks Merck is definitely on an uptrend, breaking past $100 as October ends to establish new 52-week highs. The stock’s catalyst was its sterling Q3 report last week where it beat earnings and revenues and upgraded its forecast. Year-over-year, earnings were up 4% (7% if you exclude the impact of the strong USD) and revenues rose 14% (18% considering currency). Drivers were strong sales of Merck’s cancer drugs and many vaccines. The pharmaceutical side boasted a 13% hike in sales YOY. Merck’s key drug, Keytruda, saw sales jump 20%. One of the new weaknesses in Merck was its animal health business where the strong greenback depressed sales by 3%. Read 3 Must Have Safe Stocks to Play Defensive for our full analysis.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Oct 21/21, Up 25%) Broken out to new highs. Yield is 2.8%, which should grow 8-9% over next few years. Well-positioned in immune oncology. Strong drug pipeline.

biotechnology / pharmaceutical

BUY

Their report won't disrupt their momentum. The stock is breaking out now to $100. He's maintaining his position. One of his favourite names.

biotechnology / pharmaceutical

BUY

Has owned this since the mid-$80s. It offers the perfect blend of offence and defence perfectly. Investors have ignored this, but boasts a 20% a valuation discount to the S&P. You must be defensive, and Merck is a leader in healthcare.

biotechnology / pharmaceutical

HOLD

When you're looking at pharma companies, you want to see the breadth of drugs that are in the pipeline, and any blockbuster drugs in there. You're also looking for dividends. Yield is 3.17%.

biotechnology / pharmaceutical

HOLD

Company is on watch list. Does not own shares. Current share price target on the street is ~$100. Is cheaper valued than rest of the market (12x earnings). Has lower patent rate than competitors.

biotechnology / pharmaceutical

TOP PICK

Acquisition from last year has expanded product offering. Covid-19 pandemic was hard on company, but is recovering now. Company is a defensive name as drug prices are inelastic (medications are hard to give up). Strong cash flow and dividend.

biotechnology / pharmaceutical

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Mar 24/22, Up 5.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK has triggered its stop at $855. To remain disciplined we recommend covering the position at this time. This will result in a net investment gain of 8%, when combined with previous buy recommendations.

biotechnology / pharmaceutical

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Mar 24/22, Up 13.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK is progressing well. To remain disciplined, we recommend trailing up the stop (from $80) to $85.

biotechnology / pharmaceutical

BUY

Reasonable and sustainable multiple of 12x and very good dividend. Major drug is patent-protected until at least 2026, plus great drugs in pipeline.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick May 08/20, Up 36%) Loves it. A bit pricey here. Model price of $122.65, a 31% upside. In bear markets, people go for predictable earnings. Good bear market stock. Wait for a pullback to buy, under $70. Over 3% yield.

biotechnology / pharmaceutical

Showing 1 to 15 of 231 entries

«
‹
1
2
3
4
5
›
»

Next Page

Merck & Company(MRK-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 13

Neutral - Hold Signals / Votes : 4

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 17

Stockchase rating for Merck & Company is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Merck & Company(MRK-N) Frequently Asked Questions

What is Merck & Company stock symbol?

Merck & Company is a American stock, trading under the symbol MRK-N on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK-N

Is Merck & Company a buy or a sell?

In the last year, 17 stock analysts published opinions about MRK-N. 13 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Merck & Company.

Is Merck & Company a good investment or a top pick?

Merck & Company was recommended as a Top Pick by on . Read the latest stock experts ratings for Merck & Company.

Why is Merck & Company stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Merck & Company worth watching?

17 stock analysts on Stockchase covered Merck & Company In the last year. It is a trending stock that is worth watching.

What is Merck & Company stock price?

On 2023-03-31, Merck & Company (MRK-N) stock closed at a price of $106.39.

You may also like:

WGO-N LMP-T AFSI-Q MYOK-Q RPM-X HAB-T IRE-N CRYPTOXLM CRZ-CN CRYPTODEFI

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.